Beginning next month and continuing throughout 2023, it is expected that 14 or more biosimilar versions of AbbVie’s Humira (adalimumab) will be launched to market, marking the largest loss-of-exclusivity event in the history of pharmaceuticals. As of December 13, 2022, eight biosimilars have been approved by the Food and Drug Administration. Although pricing information will likely not be available until closer to each product’s launch date, we expect that some biosimilars for Humira will be placed on ProAct’s preferred brand drug list.
| DRUG | MANUFACTURER | DATE APPROVED | EXPECTED LAUNCH DATE |
|
Amjevita |
Amgen |
09/23/2016 |
01/31/2023 |
|
Abrilada |
Pfizer |
11/15/2019 |
07/01/2023 |
|
Cyltezo |
Boehringer Ingelheim |
08/25/2017 |
07/01/2023 |
|
Hadlima |
Samsung Bioepis/Organon |
07/23/2019 |
07/01/2023 |
| Idacio | Fresenius Kabi | 12/13/2022 | 07/01/2023 |
|
Yusimry |
Coherus |
12/17/2021 |
07/01/2023 |
|
Hulio |
Viatris/Biocon |
07/06/2020 |
As early as 07/2023 |
|
Hyrimoz |
Novartis |
10/30/2018 |
As early as 07/2023 |
